نتایج جستجو برای: hiv vaccine

تعداد نتایج: 309384  

Journal: :The Journal of infectious diseases 2005
Peter B Gilbert Marta L Ackers Phillip W Berman Donald P Francis Vladimir Popovic Dale J Hu William L Heyward Faruk Sinangil Bryan E Shepherd Marc Gurwith

The first trial of the efficacy of a human immunodeficiency virus (HIV)-1 vaccine was conducted in North America and The Netherlands between 1998 and 2003. This multicenter, randomized, placebo-controlled trial of a recombinant glycoprotein 120 vaccine included 5403 initially HIV-negative volunteers who were monitored for 3 years. The 368 subjects who acquired HIV-1 infection were monitored for...

2014
Jiayi Shu Xiaojuan Fan Jie Ping Xia Jin Pei Hao

CD4+ T cells are central to the induction and maintenance of CD8+ T cell and antibody-producing B cell responses, and the latter are essential for the protection against disease in subjects with HIV infection. How to elicit HIV-specific CD4+ T cell responses in a given population using vaccines is one of the major areas of current HIV vaccine research. To design vaccine that targets specificall...

Journal: :PAMJ one health 2023

Introduction: as the coronavirus disease 2019 (COVID-19) vaccines are distributed and administered globally, hesitancy towards vaccine hinders immunisation of a significant number vulnerable populations, such people living with HIV/AIDS. Hence, this study aims to assess COVID-19 among HIV/AIDS (PLHIV) attending clinical-outpatient follow-up at State Specialist Hospital Maiduguri (SSHM), Borno S...

2014
Beatrice O. Ondondo

Development of an effective HIV/AIDS vaccine remains a big challenge, largely due to the enormous HIV diversity which propels immune escape. Thus novel vaccine strategies are targeting multiple variants of conserved antibody and T cell epitopic regions which would incur a huge fitness cost to the virus in the event of mutational escape. Besides immunogen design, the delivery modality is critica...

Journal: :Journal of virology 2015
Megan C Wise Natalie A Hutnick Justin Pollara Devin J F Myles Constance Williams Jian Yan Celia C LaBranche Amir S Khan Niranjan Y Sardesai David Montefiori Susan W Barnett Susan Zolla-Pazner Guido Ferrari David B Weiner

UNLABELLED The search for an efficacious human immunodeficiency virus type 1 (HIV-1) vaccine remains a pressing need. The moderate success of the RV144 Thai clinical vaccine trial suggested that vaccine-induced HIV-1-specific antibodies can reduce the risk of HIV-1 infection. We have made several improvements to the DNA platform and have previously shown that improved DNA vaccines alone are cap...

2017
David Easterhoff M Anthony Moody Daniela Fera Hao Cheng Margaret Ackerman Kevin Wiehe Kevin O Saunders Justin Pollara Nathan Vandergrift Rob Parks Jerome Kim Nelson L Michael Robert J O'Connell Jean-Louis Excler Merlin L Robb Sandhya Vasan Supachai Rerks-Ngarm Jaranit Kaewkungwal Punnee Pitisuttithum Sorachai Nitayaphan Faruk Sinangil James Tartaglia Sanjay Phogat Thomas B Kepler S Munir Alam Hua-Xin Liao Guido Ferrari Michael S Seaman David C Montefiori Georgia D Tomaras Stephen C Harrison Barton F Haynes

The canary pox vector and gp120 vaccine (ALVAC-HIV and AIDSVAX B/E gp120) in the RV144 HIV-1 vaccine trial conferred an estimated 31% vaccine efficacy. Although the vaccine Env AE.A244 gp120 is antigenic for the unmutated common ancestor of V1V2 broadly neutralizing antibody (bnAbs), no plasma bnAb activity was induced. The RV305 (NCT01435135) HIV-1 clinical trial was a placebo-controlled rando...

Journal: :Journal of lower genital tract disease 2011
Paul A Gilbert Noel T Brewer Paul L Reiter

OBJECTIVE Anal cancer and other diseases caused by human papillomavirus (HPV) are more common among people who are HIV-positive. To understand the potential role of HIV status in HPV prevention efforts, we examined HPV-related knowledge, attitudes, and beliefs among HIV-positive and HIV-negative gay men. MATERIALS AND METHODS In January 2009, we interviewed a national sample of 247 adult gay ...

Journal: :Vaccine 2003
José Esparza Marie-Louise Chang Roy Widdus Yvette Madrid Neff Walker Peter D Ghys

Once an effective HIV vaccine is discovered, a major challenge will be to ensure its world wide access. A preventive vaccine with low or moderate efficacy (30-50%) could be a valuable prevention tool, especially if targeted to populations at higher risk of HIV infection. High efficacy vaccines (80-90%) could be used in larger segments of the population. Estimated "needs" for future HIV vaccines...

Journal: :PLoS Medicine 2006
Barney S Graham

D evelopment of an effective HIV-1 vaccine has been an elusive goal for over 20 years despite being an urgent global priority. The agonizingly slow progress is not from lack of effort, but is a consequence of the insidious biology of the virus. HIV-1 has many features that make vaccine development challenging, if not impossible [1]. Pessimism is based in part on the empirical observation that t...

Journal: :Journal of immunology 2003
Luwy Musey Yan Ding Marnie Elizaga Richard Ha Connie Celum M Juliana McElrath

A vaccine regimen that can rapidly control HIV-1 replication at the site of exposure following sexual contact is likely to be the most effective in preventing HIV-1 infection. As part of a larger, phase II clinical trial, we evaluated the ability of a recombinant canarypox HIV-1 vaccine to induce CTL that can be detected in both the systemic and mucosal compartments following i.m. immunization ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید